{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1364233270572938752.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa020681"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa020681"}},{"identifier":{"@type":"NAID","@value":"30022558369"}}],"dc:title":[{"@value":"Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1384233270572938755","@type":"Researcher","foaf:name":[{"@value":"Patrick Marcellin"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938761","@type":"Researcher","foaf:name":[{"@value":"Ting-Tsung Chang"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938756","@type":"Researcher","foaf:name":[{"@value":"Seng Gee Lim"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938753","@type":"Researcher","foaf:name":[{"@value":"Myron J. Tong"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938624","@type":"Researcher","foaf:name":[{"@value":"William Sievert"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938762","@type":"Researcher","foaf:name":[{"@value":"Mitchell L. Shiffman"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938752","@type":"Researcher","foaf:name":[{"@value":"Lennox Jeffers"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938759","@type":"Researcher","foaf:name":[{"@value":"Zachary Goodman"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938760","@type":"Researcher","foaf:name":[{"@value":"Michael S. Wulfsohn"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938758","@type":"Researcher","foaf:name":[{"@value":"Shelly Xiong"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938757","@type":"Researcher","foaf:name":[{"@value":"John Fry"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233270572938754","@type":"Researcher","foaf:name":[{"@value":"Carol L. Brosgart"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00284793"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2003-02-27","prism:volume":"348","prism:number":"9","prism:startingPage":"808","prism:endingPage":"816"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa020681"}],"createdAt":"2003-02-27","modifiedAt":"2016-11-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002218199423872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714657048832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140544000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical course and predictive factors of virological response in long‐term lamivudine plus adefovir dipivoxil combination therapy for lamivudine‐resistant chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185445755776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189430726656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256572160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256676992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256779904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643093195008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846645722372480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"TGF-β/Smad signaling during hepatic fibro-carcinogenesis (Review)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656946869504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"2′-Fluoro-6′-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: In vitro anti-HBV activity against the lamivudine–entecavir resistant triple mutant and its mechanism of action"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788892288","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Forefront of the viral chronic hepatitis treatment. Treatment of the case for which the treatment plans can not be decided. 2. Treatment of the case which is negative in HBe antigen and repeats liver function abnormality."},{"@value":"ウイルス性慢性肝炎治療の最先端―治療方針に迷う症例に対する治療―２．ＨＢｅ抗原陰性，肝機能異常を繰り返す症例に対する治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204788908032","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case which could be rescued by adefovir dipivoxil and plasma exchange from chronic hepatitis B that developed fulminant hepatic failure due to breakthrough infection caused by YMDD motif mutation during lamivudine therapy"},{"@value":"ラミブジン治療後にＹＭＤＤ変異株によるｂｒｅａｋｔｈｒｏｕｇｈ肝炎の劇症化を来したがＡｄｅｆｏｖｉｒ　ｄｉｐｉｖｏｘｉｌと血しょう交換療法が奏効したＢ型慢性肝炎の１例"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204790262400","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A non-Hodgkin lymphoma patient with reactivation of HBV during chemotherapy and emergence of a YMDD-motif mutant on lamivudine, eventually controlled by adfovil dipovoxil"},{"@language":"ja","@value":"ＮＨＬに対する化学療法中にＹＭＤＤ変異によりＨＢＶ再活性化をきたし，ａｄｅｆｏｖｉｒ　ｄｉｐｉｖｏｘｉｌ追加投与にて改善した１例"},{"@value":"症例報告 NHLに対する化学療法中にYMDD変異によりHBV再活性化をきたし,adefovir dipivoxil追加投与にて改善した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク NHL ニ タイスル カガク リョウホウチュウ ニ YMDD ヘンイ ニ ヨリ HBV サイカッセイカ オ キタシ adefovir dipivoxil ツイカ トウヨ ニテ カイゼンシタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792496896","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"慢性Ｂ型肝炎に対するラミブジン治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204871665152","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Decompensated Lamivudine-resistant Hepatitis B Virus-related Cirrhosis Treated Successfully with Adefovir Dipivoxil Allowing Surgery for Hepatocellular Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204873592576","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Treatment with Adefovir of One Patient Whose Cryoglobulinemic Vasculitis Relapsed under Lamivudine Therapy and Who was Diagnosed to Have HBV Virologic Breakthrough with YMDD Mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205369123968","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacokinetics of Adefovir after Oral Administration of Adefovir Dipivoxil 10 mg in Healthy Japanese Males and Japanese Patients with Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205746563840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recent Advances in Hepatitis B Research"},{"@language":"ja","@value":"わが国におけるB型肝炎研究の最近の動向"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679216130816","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Genotype-Associated Variability in Antiviral Response to Adefovir Dipivoxil Therapy in Chinese Han Population"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679767509376","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Staging of hepatitis B virus carriers based on HBV markers and cancer risk-A system to assist in the selection of appropriate antiviral treatment-"},{"@value":"ＨＢＶマーカーと発癌リスクよりみたＨＢＶキャリアのステージ分類―適切な抗ウイルス治療の選択に向けて―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679769900032","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil"},{"@language":"ja","@value":"アデホビルによる腎障害の検討"},{"@language":"ja-Kana","@value":"アデホビル ニ ヨル ジン ショウガイ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771909888","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma"},{"@language":"ja","@value":"多剤耐性変異を認めた悪性リンパ腫合併Ｂ型慢性肝炎に対しテノフォビルが著効した一例"},{"@value":"症例報告 多剤耐性変異を認めた悪性リンパ腫合併B型慢性肝炎に対しテノフォビルが著効した一例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク タザイ タイセイ ヘンイ オ ミトメタ アクセイ リンパ シュ ガッペイ Bガタ マンセイ カンエン ニ タイシ テノフォビル ガ チョコウシタ イチレイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679846719360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Overlap/Switch to Adefovir Monotherapy for Lamivudine-resistant Patients Who Responded to Combination Therapy: A Pilot Controlled Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679849678208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hypophosphatemic Osteomalacia Due to Drug-induced Fanconi's Syndrome Associated with Adefovir Dipivoxil Treatment for Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679850702592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713058047104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency"}]},{"@id":"https://cir.nii.ac.jp/crid/1390857063645588992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750573120896","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Combination therapy with lamivudine and HB vaccine on chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650385414656","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Liver transplantation for hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261550386807424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Improving outcomes for patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500083016576","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975317212928","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Appropriate use of interferon for treatment of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975837321088","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa020681"},{"@type":"CIA","@value":"30022558369"},{"@type":"CROSSREF","@value":"10.1111/j.1365-2893.2010.01301.x_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.49.3342_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.14789/pjmj.55.443_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.55.6301_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.48.309_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.35_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1016/j.bmcl.2012.11.027_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1698-18_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1620/tjem.2022.j084_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1002/jmv.22025_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1111/cei.12259_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.3390/cancers10060183_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.52.102_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1620/tjem.216.205_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.46.6079_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.3851/imp3225_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1007/s00535-011-0522-7_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1007/s00535-013-0864-4_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1273-2_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.1111/hepr.12902_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.3892/ijo.2014.2552_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.53.1213_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.45.1816_references_DOI_2b3xeHB8dYKJ6gyZn3OWg0ySPtJ"}]}